

CONFIDENTIAL

## QUALITY POLICY

**MicroViable Therapeutics S.L.** (hereinafter "MicroViable") is a preclinical biotechnology company developing novel microbiota-based biological medicines to improve human health.

**MicroViable** was founded in 2016 as a spin-off of the Institute of Dairy Products of Asturias (IPLA), part of the Spanish National Research Council (CSIC), and comprises a multidisciplinary team of scientists specializing in the field of gut microbiota and human health.

**MicroViable's research** focuses on all diseases and physiological conditions in which the microbiota exerts a modulating effect, with two clearly defined therapeutic lines: infectious diseases and oncology. Product development is centered on these areas, always with the aim of generating new microbiota-based biological medicines as therapeutic solutions for human health.

MicroViable's core principles are:

- The close relationship with different Foundations and Public Research Organizations in R&D activities.
- The in vitro diagnostic medical devices and services supplied to our customers are safe, reliable and comply with applicable specifications, standards and legislation.
- The development of investigational drugs based on the purification of intestinal microbiota using protocols that allow obtaining safe and clinically viable products, guaranteeing the quality and traceability necessary for their therapeutic use.
- Closeness to our stakeholders and thorough analysis of their needs and expectations to provide a prestigious service.
- The achievement of excellent working conditions and environment that enable high satisfaction of the multidisciplinary team that makes up MicroViable.
- Improving the quality of healthcare products and services provided through data analysis and the identification of areas for improvement, in collaboration with the stakeholders involved.

We strive for continuous improvement of our processes and the maintenance of a Quality Management System that complies with the requirements established by the UNE-EN ISO 9001 standard (Quality management systems, requirements), the scope of which is defined as "Design, manufacture, and marketing of in vitro diagnostic medical devices (Kit for the collection and transport of fecal material under anaerobic conditions). Purification of intestinal microbiota for human health applications".

This quality policy is reviewed at least once a year, is disseminated through its publication on the MicroViable website, and provides the framework for establishing quality objectives.

in Gijón (Asturias), on 9<sup>th</sup> April, 2026

